1,721,076 research outputs found
Letter to the editor (multiple letters)
No full textfurther study is necessary before widespread
clinical use of heparin in diabetic nephropathy. Improved knowledge of the structure-function relationship of heparin and glycosaminoglycans and a doseresponse finding of these drugs might provide a unique
opportunity to select new heparin derivatives with
specific effects on diabetic nephropathy and possibly,
most importantly, devoid of anticoagulant activit
Glycosaminoglycans: A new paradigm in the prevention of proteinuria and progression of glomerular disease
No full textNutrition and calcium nephrolithiasis: The lipid hypothesis
No full textA review on the role of cell membrane lipid composition of ion handlings and risk of nephrolithiasi
TRANSMEMBRANE OXALATE EXCHANGE AND ITS RELATIONSHIP TO IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS
No full text
CALCOLOSI DELLE VIE URINARIE
No full textInquadramento generale e specifico degli aspettu metabolici della nefrolitias
IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS - A CELLULAR-DISEASE
Full text linkPhysico-chemical, metabolic and hormonal theories regarding the pathogenesis of calcium oxalate nephrolithiasis do not sufficiently explain many features of this disease. The recent findings of an abnormally faster oxalate self-exchange and higher phosphorylation of band 3 in erythrocytes of idiopathic calcium oxalate stone formers suggest the hypothesis that nephrolithiasis may be a cellular disease, characterized by a defect in the function of the anion-exchange. The cellular anomaly seems genetically controlled. Band 3 anion exchanger function seems to be biochemically regulated through modulation of band 3 phosphorylation, which depends on cyclic AMP- and phospholipid-sensitive Ca2+ independent protein kinases. In this light, a reduced glycosaminoglycan concentration in the erythrocyte membranes of stone formers might play a role, as these molecules exert a strong inhibitory effects on band 3 phosphorylation and anion transport in vitro and in vivo. An in vivo trial was performed in which stone formers were administered glycosaminoglycans orally. A reduction in oxalate excretion, and oxalate renal clearance, and a simultaneous correction of the abnormal RBC oxalate flux and band 3 phosphorylation were observed. These data suggest the existence of a link between the erythrocyte abnormality and oxalate transport by the kidney and gut
- …
